Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Intra-Individual Variability of the Utility Weighted Modified Rankin Scale in the Initial Post-Stroke Period
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
203
To characterize intra-individual variability of the utility-weighted modified Rankin Scale (UW-mRS) between day 30 and 90 post-stroke.
The UW-mRS links health-related quality of life (HRQoL) to the mRS score by assigning a health utility weighting. An individual’s perception of health utility for a given mRS could potentially change over time, thus impacting their UW-mRS score.
Participant-level data were collected as part of the ESCAPE trial. Participants with a stable mRS score between day 30 and 90 post-stroke (i.e. with the same mRS score at both time points) who had EQ-5D scores for both days 30 and 90 were analyzed. Utility weights were calculated from the EQ-5D scores. Wilcoxon rank-sum tests were used to compare median UW-mRS scores between time points. UW-mRS within-participant stability over time was assessed with a one-way random intra-class correlation (ICC).
In total, 315 participants were enrolled in ESCAPE. Of the 272 participants who survived to day 30, 133 had a stable mRS at day 90, with 101 having EQ-5D scores for both time points. Median EQ-5D scores between days 30 and 90 were: 1.00-1.00 (mRS 0), 0.84-0.85 (mRS 1), 0.83-0.82 (mRS 2), 0.69-0.63 (mRS 3), 0.44-0.44 (mRS 4) and 0.15-0.18 (mRS 5). At each mRS level, UW-mRS were not significantly (p>0.05) different between time points. ICC for UW-mRS between day 30 and day 90 was 0.84 (95% CI: 0.77-0.89). Participants ≥80 years old, with mRS 5 or with left hemispheric events were more likely to have a missing EQ-5D.
In the first 90 days post-stroke, stroke survivors with stable mRS functional status demonstrated minimal intra-individual variability in their UW-mRS, suggesting apparent stability in HRQoL. Given the non-randomness of missing data, how older and severely disabled patients perceive stability in HRQoL as they adapt to their new functional status post-stroke remains less clear.
Authors/Disclosures
Alexander Rebchuk, MD, MSc
PRESENTER 		Dr. Rebchuk has nothing to disclose.
Raed Joundi, MD, PhD Dr. Joundi has nothing to disclose.
Michael D. Hill, MD (University of Calgary) Dr. Hill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular.
Thalia S. Field, MD (University of British Columbia) Dr. Field has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Field has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Field has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Field has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Field has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZeneca. Dr. Field has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Canadian Medical Protective Association, plaintiff. The institution of Dr. Field has received research support from Vancouver Coastal Health Research Institute, Heart and Stroke Foundation of Canada, Brain Canada and CIHR. Dr. Field has a non-compensated relationship as a Editorial board with Stroke that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Field has a non-compensated relationship as a Editorial board with CJNS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Field has a non-compensated relationship as a Editorial board with JNNP that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Field has a non-compensated relationship as a Board member with DESTINE Health that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Field has a non-compensated relationship as a Board Member with Vancouver General Hospital Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.